Table 2.
Human miRNAs used in the study
| hsa- | No. of targets | |
|---|---|---|
| |
miR-99a |
71 |
| |
miR-181a* |
85 |
| |
miR-125b-1* |
137 |
| |
miR-424* |
151 |
| |
miR-155 |
153 |
| |
miR-21* |
177 |
| |
miR-181a |
245 |
| |
miR-29b |
273 |
| |
miR-221 |
302 |
| |
miR-181b |
308 |
| |
miR-222* |
314 |
| A |
miR-886-3p |
334 |
| |
miR-221* |
378 |
| |
miR-199a-3p |
408 |
| |
miR-484 |
408 |
| |
miR-708 |
446 |
| |
miR-214* |
463 |
| |
miR-503 |
478 |
| |
miR-320a |
493 |
| |
miR-214 |
624 |
| |
miR-29b-1* |
633 |
| |
miR-34a |
840 |
| |
miR-100 |
68 |
| |
miR-21 |
109 |
| B |
miR-223 |
118 |
| |
miR-101 |
196 |
| |
miR-199a-5p |
256 |
| miR-222 | 340 |
Human miRNAs used in the study, that were shown to be down-regulated upon HCMV infection in at least one of the three expression data sources (data supplied in this study, by Wang et al. [31] and by Santhakumar et al. [32]). A) miRNAs that were classified as down regulated in the miRNA expression data supplied in this study (see Methods). B) Additional miRNAs that were classified as down regulated in the studies of Wang et al[31] and Santhakumar at el [32]. Each group is sorted by the number of targets.